T3 Pharma Nears The Clinic With Live Bacteria To Treat Cancer
Five-Year-Old Swiss Biotech Raises CHF25m To Pursue Novel Approach
Using live bacteria modified to deliver specific proteins to treat cancer is to be explored by the Swiss start-up, T3 Pharmaceuticals, which has garnered a large third round of funding from a European corporate VC, institutional and private investors, to advance its lead candidate into clinical trials.
